000060895 001__ 60895
000060895 005__ 20200221144255.0
000060895 0247_ $$2doi$$a10.3791/54440
000060895 0248_ $$2sideral$$a96690
000060895 037__ $$aART-2016-96690
000060895 041__ $$aeng
000060895 100__ $$0(orcid)0000-0001-7866-2803$$aUranga, S.$$uUniversidad de Zaragoza
000060895 245__ $$aProtective efficacy and pulmonary immune response following subcutaneous and intranasal BCG administration in mice
000060895 260__ $$c2016
000060895 5060_ $$aAccess copy available to the general public$$fUnrestricted
000060895 5203_ $$aDespite global coverage of intradermal BCG vaccination, tuberculosis remains one of the most prevalent infectious diseases in the world. Preclinical data have encouraged pulmonary tuberculosis vaccines as a promising strategy to prevent pulmonary disease, which is responsible for transmission. In this work, we describe the methodology used to demonstrate in the mouse model the benefits of intranasal BCG vaccination when compared to subcutaneous. Our data revealed greater protective efficacy following intranasal BCG administration. In addition, our results indicate that pulmonary vaccination triggers a higher immune response in lungs, including Th1 and Th17 responses, as well as an increase of immunoglobulin A (IgA) concentration in respiratory airways. Our data show correlation between protective efficacy and the presence of IL17- producing cells in lungs post-Mycobacterium tuberculosis challenge, suggesting a role for this cytokine in the protective response conferred by pulmonary vaccination. Finally, we detail the global workflow we have developed to study respiratory vaccination in the mouse model, which could be extrapolated to other tuberculosis vaccines, apart from BCG, targeting the mucosal response or other pulmonary routes of administration such as the intratracheal or aerosol.
000060895 536__ $$9info:eu-repo/grantAgreement/ES/MINECO/BIO2014-5258P$$9This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 643381-TBVAC2020$$9info:eu-repo/grantAgreement/EC/H2020/643381/EU/TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development/TBVAC2020
000060895 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000060895 590__ $$a1.232$$b2016
000060895 591__ $$aMULTIDISCIPLINARY SCIENCES$$b27 / 63 = 0.429$$c2016$$dQ2$$eT2
000060895 592__ $$a0.866$$b2016
000060895 593__ $$aChemical Engineering (miscellaneous)$$c2016$$dQ1
000060895 593__ $$aImmunology and Microbiology (miscellaneous)$$c2016$$dQ2
000060895 593__ $$aBiochemistry, Genetics and Molecular Biology (miscellaneous)$$c2016$$dQ2
000060895 593__ $$aNeuroscience (miscellaneous)$$c2016$$dQ3
000060895 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000060895 700__ $$0(orcid)0000-0001-8644-120X$$aMarinova, D.$$uUniversidad de Zaragoza
000060895 700__ $$0(orcid)0000-0003-2993-5478$$aMartin, C.$$uUniversidad de Zaragoza
000060895 700__ $$0(orcid)0000-0001-7897-9173$$aAguilo, N.$$uUniversidad de Zaragoza
000060895 7102_ $$11008$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cÁrea Microbiología
000060895 7102_ $$11008$$2X$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cProy. investigación HQA
000060895 773__ $$g2016, 115 (2016), e54440$$pJ. vis. exp.$$tJournal of visualized experiments : JoVE$$x1940-087X
000060895 8564_ $$s443098$$uhttps://zaguan.unizar.es/record/60895/files/texto_completo.pdf$$yVersión publicada
000060895 8564_ $$s18962$$uhttps://zaguan.unizar.es/record/60895/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000060895 909CO $$ooai:zaguan.unizar.es:60895$$particulos$$pdriver
000060895 951__ $$a2020-02-21-13:29:59
000060895 980__ $$aARTICLE